# Summary of Recommendations for Child/Teen Immunization* (Age birth through 18 years)

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>Schedule for routine vaccination and other guidelines</th>
<th>Schedule for catch-up vaccination and related issues</th>
<th>Contraindications and precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COVID-19</strong></td>
<td>Current recommendations for vaccination against COVID-19 can be found at <a href="http://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html">www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html</a>.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Hepatitis B (HepB)** | Give IM | • Do not restart series, no matter how long since previous dose. 
• 3-dose series can be started at any age. 
• Minimum intervals between doses: 4wks between #1 and #2, 8wks between #2 and #3, and at least 16wks between #1 and #3 (and give dose #3 no earlier than age 24wks). | **Contraindication** 
• History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. Severe allergy to yeast is a contraindication to all HepB-containing vaccines except PreHevBrio. **Precautions** 
• Moderate or severe acute illness, with or without fever. 
• For infants who weigh less than 2000g, see ACIP recommendations at www.cdc.gov/mmwr/pdf/rr/rr5416.pdf. **Pregnancy:** Data on Heplisav-B and PreHevBrio (for age 18 and older) are currently insufficient to reach any conclusions concerning vaccine-associated risks in pregnancy; providers are advised to use other HepB brands. |
| **DTaP, DT (Diphtheria, tetanus, acellular pertussis)** | Give IM | • If dose #4 is given before 4th birthday, wait at least 6m for #5 (age 4–6yrs). 
• If dose #4 is given after 4th birthday, #5 is not needed. | **Contraindications** 
• History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. 
• For DTaP and Tdap only: Encephalopathy not attributable to an identifiable cause, within 7d after DT, DTaP, or Tdap. **Precautions** 
• Moderate or severe acute illness. 
• History of Arthus reaction following a prior dose of diphtheria-toxoid–containing or tetanus-toxoid–containing vaccine; defer vaccination until at least 10yrs have elapsed since the last tetanus-toxoid–containing vaccine. 
• Guillain-Barré syndrome (GBS) within 6wks after previous dose of tetanus-toxoid–containing vaccine. 
• For DTaP only: Progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy, defer DTaP until neurologic status clarified and stabilized. |
| **Td, Tdap (Tetanus, diphtheria, acellular pertussis)** | Give IM | • Do not restart series, no matter how long since previous dose. 
• 3-dose series can be started at any age. 
• Minimum intervals between doses: 4wks between #1 and #2, 8wks between #2 and #3, and at least 16wks between #1 and #3 (and give dose #3 no earlier than age 24wks). | **Contraindication** 
• History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. Severe allergy to yeast is a contraindication to all HepB-containing vaccines except PreHevBrio. **Precautions** 
• Moderate or severe acute illness, with or without fever. 
• For infants who weigh less than 2000g, see ACIP recommendations at www.cdc.gov/mmwr/pdf/rr/rr5416.pdf. **Pregnancy:** Data on Heplisav-B and PreHevBrio (for age 18 and older) are currently insufficient to reach any conclusions concerning vaccine-associated risks in pregnancy; providers are advised to use other HepB brands. |

*This document was adapted from the vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). To view the full vaccine recommendations and guidelines, visit CDC’s website at www.cdc.gov/vaccines/hcp/ACIP-rcs/index.html. It does not include information on dengue vaccine which is recommended for specific children living in dengue endemic areas (see ACIP recommendations in link above and also the ACIP’s “Recommendations for Children and Adolescent Immunization Schedule” at www.cdc.gov/vaccines/schedules/hcp/index.html. For the purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Immunize.org FOR PROFESSIONALS www.immunize.org FOR THE PUBLIC www.vaccineinformation.org **For the public** www.immunize.org/catg.d/p2010.pdf • Item #P2010 (6/22) |
### Rotavirus (RV)
**Give orally**
- **Rotarix (RV1):** Give at ages 2m, 4m.
- **RotaTeq (RV5):** Give at ages 2m, 4m, 6m.
- May give dose #1 as early as age 6wks.
- Give final dose no later than age 8m, 0d.
- Do not begin series in infants older than age 14wks 6d.
- Intervals between doses may be as short as 4wks.
- If prior vaccination included use of different or unknown brand(s), a total of 3 doses should be given.

**Contraindications**
- History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component.
- History of intussusception.
- Severe combined immunodeficiency (SCID).

**Precautions**
- Moderate or severe acute illness, with or without fever.
- Altered immunocompetence other than SCID.
- Chronic gastrointestinal disease.
- For RV1 only, spina bifida or bladder extrophy.

### Hib (Haemophilus influenzae type b)
**Give IM**
- **ActHib (PRP-T), Hiberial, Pentacel, or Vaxelis:** Give at age 2m, 4m, 6m, 12–15m (booster dose). Vaxelis is not recommended for booster dose; use a different Hib-containing vaccine.
- **PedvaxHIB (containing PRP-OMP):** Give at age 2m, 4m, 12–15m (booster dose).
- Dose #1 of Hib vaccine should not be given earlier than age 6wks.
- Give final dose (booster dose) no earlier than age 12m and a minimum of 8wks after the previous dose.
- Hib vaccines are interchangeable; however, if different brands of Hib vaccines are administered for dose #1 and dose #2, a total of 3 doses is necessary to complete the primary series in infants, followed by a booster after age 12m.
- For vaccination of children 12 through 59m who are immunocompromised (immunoglobulin deficiency, complement component deficiency, HIV infection, receipt of chemotherapy or radiation therapy for cancer) or asplenic: if previously received no doses or only 1 dose before age 12m, give 2 additional doses at least 8wks apart; if previously received 2 or more doses before age 12m, give 1 additional dose.
- Hib is not routinely given to healthy children age 5yrs and older.
- 1 dose of Hib vaccine should be administered to children age 5yrs and older who have anatomic or functional asplenia (including sickle cell disease) and who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after age 14m.
- 1 dose of Hib vaccine should be administered to unvaccinated persons 5 through 18yrs of age with HIV infection.

**Contraindications**
- History of severe allergic reaction (e.g., anaphylaxis) to a previous dose, to a vaccine component.
- Age younger than 6wks.

**Precautions**
- Moderate or severe acute illness, with or without fever.

**Note:** Recipients of hematopoietic stem cell transplant should receive 3 doses of Hib vaccine at least 4wks apart beginning 6–12m after transplant, regardless of Hib vaccination history.
<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>Schedule for routine vaccination and other guidelines (any vaccine can be given with another, unless otherwise noted)</th>
<th>Schedule for catch-up vaccination and related issues</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
</table>
| Varicella (Var; MMRV) (Chickenpox) Give Subcut | • Give dose #1 at age 12–15m.  
• Give dose #2 at age 4–6yrs. Dose #2 of Var or MMRV may be given earlier if at least 3m since dose #1. If dose #2 was given at least 4wks after dose #1, it can be accepted as valid.  
• Give a 2nd dose to all older children/teens with history of only 1 dose.  
• MMRV may be used in children age 12m through 12yrs (see note below). | • If younger than age 13yrs, space dose #1 and #2 at least 3m apart. If age 13yrs or older, space at least 4wks apart.  
• May use as postexposure prophylaxis if given within 5d.  
• If Var and either LAIV, MMR, and/or yellow fever vaccine are not given on the same day, space them at least 28d apart. If yellow fever vaccine, space by 30d. | • History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component.  
• Pregnancy  
• Severe immunodeficiency (e.g., hematologic and solid tumors; receiving chemotherapy; congenital immunodeficiency; long-term immunosuppressive therapy, or severely symptomatic HIV).  
• Family history of congenital or altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent. |
| MMR (Measles, mumps, rubella; MMRV) Give Subcut | • Give dose #1 at age 12–15m.  
• Give MMR at age 6–11m if traveling internationally; revaccinate with 2 doses of MMR at age 12–15m and at least 4wks later. The dose given at younger than 12m does not count toward the 2-dose series.  
• Give dose #2 at age 4–6yrs. Dose #2 may be given earlier if at least 4wks since dose #1. For MMRV: dose #2 may be given earlier if at least 3m since dose #1.  
• Give a 2nd dose to all older children and teens with history of only 1 dose.  
• MMRV may be used in children age 12m through 12yrs (see note above). | • If MMR and either LAIV, Var, and/or yellow fever vaccine are not given on the same day, space them at least 28d apart. If yellow fever vaccine, space by 30d.  
• When using MMR for both doses, minimum interval is 4wks.  
• When using MMRV for both doses, minimum interval is 3m.  
• May use as postexposure measles prophylaxis if given within 3d. | • History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component.  
• Pregnancy  
• Severe immunodeficiency (e.g., hematologic and solid tumors; receiving chemotherapy; congenital immunodeficiency; long-term immunosuppressive therapy, or HIV with severe immunocompromise).  
• Family history of congenital or altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent. |

**NOTE:** For the first dose of MMR and varicella given at age 12–47m, either MMR and Var or MMRV may be used. Unless the parent or caregiver expresses a preference for MMRV, CDC recommends that MMR and Var be used for the first doses in this age group.

**CONTRAINDICATIONS:**

- Use of aspirin or aspirin-containing products.
- Need for tuberculin skin testing (TST) or interferon-gamma release assay (IGRA) testing. If TST or IGRA needed, give TST or IGRA before or on same day as MMR, or give TST or IGRA 4wks following MMR.

**PRECAUTIONS:**

- Moderate or severe acute illness, with or without fever.
- Recent (within 11m) receipt of antibody-containing blood product (specific interval depends on product; see ACIP’s General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf regarding time to wait before vaccinating).
- Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24hrs before vaccination (avoid use of these antiviral drugs for 14d after vaccination).
### Summary of Recommendations for Child/Teen Immunization* (Age birth through 18 years)

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>Schedule for routine vaccination and other guidelines (any vaccine can be given with another, unless otherwise noted)</th>
<th>Schedule for catch-up vaccination and related issues</th>
<th>Contraindications and precautions (mild illness is not a contra-indication)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pneumococcal conjugate</strong> (PCV13)</td>
<td><strong>High-risk</strong>&lt;br&gt;For both PCV13 and PPSV23 in children ages 2–18yrs: those with sickle cell disease; anatomic or functional asplenia; chronic renal failure or nephrotic syndrome; cerebrospinal fluid leaks; HIV infection; immunosuppression; diseases associated with immunosuppressive treatment and/or radiation therapy, including cancer; asthma, if taking high dose corticosteroids; solid organ transplantation; or who have or will have a cochlear implant.</td>
<td></td>
<td><strong>Contraindication</strong>&lt;br&gt;History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. <strong>Precaution</strong>&lt;br&gt;Moderate or severe acute illness, with or without fever.</td>
</tr>
<tr>
<td>Prevnar 13 Give IM</td>
<td>• Give at ages 2m, 4m, 6m, 12–15m (booster dose).&lt;br&gt;• Dose #1 may be given as early as age 6wks.&lt;br&gt;• For age 24 through 59m and healthy: if unvaccinated or any incomplete schedule of 3 doses of PCV 13 was received previously, give 1 supplemental dose of PCV13 at least 8wks after the most recent dose.&lt;br&gt;• For high-risk** children ages 2 through 5yrs: give 2 doses at least 8wks apart if they previously received an incomplete schedule of fewer than 3 doses; give 1 dose at least 8wks after the most recent dose if they previously received 3 doses.&lt;br&gt;• For high-risk** children: all recommended PCV13 doses should be given prior to PPSV vaccination.&lt;br&gt;• PCV13 is not routinely given to healthy children age 5yrs and older.</td>
<td></td>
<td><strong>Contraindication</strong>&lt;br&gt;History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. <strong>Precaution</strong>&lt;br&gt;Moderate or severe acute illness, with or without fever.</td>
</tr>
<tr>
<td><strong>Pneumococcal polysaccharide</strong> (PPSV23)</td>
<td><strong>For both PCV13 and PPSV23 in 2–5yrs</strong>&lt;br&gt;<strong>For PPSV23 only in 6–18yrs</strong>&lt;br&gt;Those with chronic cardiac or pulmonary disease; diabetes</td>
<td></td>
<td><strong>Contraindication</strong>&lt;br&gt;History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. <strong>Precaution</strong>&lt;br&gt;Moderate or severe acute illness, with or without fever.</td>
</tr>
<tr>
<td>Pneumovax 23 Give IM or Subcut</td>
<td>• Give 1 dose at least 8wks after final dose of PCV13 to high-risk** children age 2yrs and older.&lt;br&gt;• For children who have sickle cell disease, functional or anatomic asplenia, HIV infection, or other immunocompromising condition, give a 2nd dose of PPSV 5yrs after previous PPSV (see ACIP pneumococcal recommendations at <a href="http://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf">www.cdc.gov/mmwr/pdf/rr/rr5911.pdf</a>).</td>
<td></td>
<td><strong>Contraindication</strong>&lt;br&gt;History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. <strong>Precaution</strong>&lt;br&gt;Moderate or severe acute illness, with or without fever.</td>
</tr>
<tr>
<td><strong>Human papillomavirus</strong> (HPV)</td>
<td><strong>For ages 6 through 11yrs:</strong> Give 1 dose at age 11 or 12yrs.&lt;br&gt;<strong>For ages 12 through 23m:</strong> Give a 2-dose series of HPV to all persons through age 26yrs who were not previously vaccinated.&lt;br&gt;<strong>Other guidance:</strong> Pregnancy is neither a contraindication nor a precaution to HPV vaccine, but vaccination should be delayed until after pregnancy.</td>
<td>• Minimum intervals between doses: 2-dose schedule: 5m; 3-dose schedule: 4wks between #1 and #2; 12wks between #2 and #3 and 5m between #1 and #3.</td>
<td><strong>Contraindication</strong>&lt;br&gt;History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component. <strong>Precaution</strong>&lt;br&gt;Moderate or severe acute illness, with or without fever.</td>
</tr>
</tbody>
</table>

---

*For professionals www.immunize.org / For the public www.vaccineinformation.org*
### Hepatitis A (HepA)  
**Give IM**

- Give 2 doses spaced 6–18m apart to all children at age 1yr (12–23m).
- Vaccinate all previously unvaccinated children and adolescents age 2 through 18yrs.
- Give 1 dose to children age 6–11m who travel outside the U.S. to countries with high or intermediate HepA endemicity. This dose does not count toward the routine 2-dose series given at age 1yr.

### Inactivated polio (IPV)  
**Give Subcut or IM**

- Give to children at ages 2m, 4m, 6–18m, 4–6yrs.
- May give dose #1 as early as age 6wks.
- Not routinely recommended for U.S. residents age 18yrs and older (except certain travelers). For information on polio vaccination for international travelers, see wwwnc.cdc.gov/travel/diseases/poliomyelitis.
- Doses of oral poliovirus vaccine (OPV) administered outside the U.S. before Apr. 1, 2016 may be counted toward the IPV series, unless OPV specifically noted as part of a campaign.

### Influenza

#### Inactivated influenza vaccine (IIV)  
**Give IM**  
IIV includes recombinant influenza vaccine (RIV) for teens ages 18yrs and older  
Live attenuated influenza vaccine (LAIV)  
**Give NAS (intranasally)**

- Vaccinate all children and teens age 6m and older.
- For children age 6m through 8yrs, give 2 doses of age-appropriate vaccine, spaced 4 wks apart, who 1) are first-time vaccinees, or 2) have received only one lifetime dose previous to this current season (season runs July to June).
- For IIV in children age 6–35m, give one of the following: Afluria 0.25 mL dose, Fluarix 0.5 mL dose, Fluval 0.5 mL dose, FluLaval 0.5 mL dose, or FluZone 0.25 or 0.5 mL dose.
- For IIV in children age 3yrs and older, give 0.5 mL dose of any age-appropriate influenza vaccine.
- For LAIV in children age 2yrs and older, give 0.2 mL nasal spray dose.
- For teens age 18yrs and older: recombinant influenza vaccine (RIV) may also be used.

#### Other guidance:
- Children with functional or anatomic asplenia, complement deficiency, cochlear implant, or CSF leak should not receive LAIV.
- Children with egg allergy of any severity can receive any age-appropriate influenza vaccine (i.e., any IIV, RIV, or LAIV) that is otherwise appropriate for their health status. People having had a previous severe reaction to eggs involving symptoms other than hives should be administered vaccine in a medical setting (e.g., a health department or physician office) and should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions, unless receiving egg-free cIIV or RIV.
- For children/teens who experience only hives with exposure to eggs, give any age-appropriate influenza vaccine.

#### Contraindications and precautions

- **Contraindication**
  - History of Guillain-Barré syndrome (GBS) within 6wks of a previous influenza vaccination.
  - For cIIV4 and RIV4: History of a severe allergic reaction (e.g., anaphylaxis) to any IIV, cIIV, RIV, or LAIV of any valency or to a vaccine component (except egg) is a contraindication to further doses of the same vaccine.
  - For egg-based IIV, prior severe allergic reaction to LAIV; for LAIV, prior severe reaction to egg-based IIV.
  - For LAIV only: Functional or anatomic asplenia; active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear, or any other cranial CSF leak; cochlear implant; immunosuppression (including that caused by medications or HIV); close contacts or caregivers of severely immunosuppressed people who require a protected environment; pregnancy; for children and teens ages 6m through 18yrs, current aspirin or salicylate-containing medication; for children age 2 through 4yrs, a history of asthma or wheezing; receipt of zanamivir and oseltamivir within 48hrs, peramivir within 5d, or baloxavir within 17d (if use of any of these antiviral drugs within 14d after LAIV, revaccinate with IIV).

- **Precautions**
  - Moderate or severe acute illness, with or without fever.
  - History of Guillain-Barré syndrome (GBS) within 6wks of a previous influenza vaccination.
  - For cIIV4 and RIV4: History of a severe allergic reaction (e.g., anaphylaxis) to any IIV, LAIV, or RIV is a precaution for cIIV; or a severe allergic reaction (e.g., anaphylaxis) to any IIV, LAIV, or cIIV is a precaution for RIV. If administering cIIV or RIV, administer in a medical setting under the supervision of a healthcare provider who can recognize and manage severe allergic reactions.
  - For LAIV only: Chronic pulmonary (including asthma in children age 5yrs and older), cardiovascular (except hypertension), renal, hepatic, neurological/neuromuscular, hematologic or metabolic (including diabetes) disorders.
### Meningococcal conjugate, quadrivalent (MenACWY)

- **MenACWY-D (Menactra)**
- **MenACWY-CRM (Menveo)**
- **MenACWY-TT (MenQuadfi)**

**Give IM**

- Give a 2-dose series of MenACWY with dose #1 at age 11–12yrs and dose #2 at age 16yrs.
- If unvaccinated at 11–12yrs, give dose #1 at age 13 through 15yrs. Give dose #2 at 16 through 18yrs with a minimum interval of at least 8wks between doses.
- If unvaccinated at 11 through 15yrs, give dose #1 at 16 through 18yrs.
- For first year college students living in a residence hall, regardless of age:
  - If unvaccinated, give 1 dose.
  - If history of 1 dose given when younger than age 16, give dose #2.
  - If most recent dose given after 16th birthday and more than 5 years have elapsed, give 1 dose.
- Give Menveo to children age 2–18m with persistent complement component deficiency, complement inhibitor use, HIV infection, or anatomic/functional asplenia; give at ages 2, 4, 6, 12–15m.
- For unvaccinated or partially vaccinated children age 7–23m with persistent complement component deficiency: 1) if age 7–23m and using Menveo, give a 2-dose series at least 3m apart with dose #2 given after age 12m or, 2) if age 9–23m and using Menactra, give a 2-dose series at least 3m apart. Give any brand of MenACWY to unvaccinated children age 24m and older with persistent complement component deficiency or anatomic or functional asplenia; give 2 doses, 2m apart. If Menactra is given, it must be separated by 4wks from the final dose of PCV13.
- Give age-appropriate series of meningococcal conjugate vaccine (brand must be licensed for age of child) to 1) children age 2m and older at risk during a community outbreak attributable to a vaccine serogroup and 2) children age 2m and older traveling to or living in countries with hyperendemic or epidemic meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj.

### Meningococcal serogroup B (MenB)

- **MenB-4C (Bexsero)**
- **MenB-FHbp (Trumenba)**

**Give IM**

- Teens age 16 through 18yrs may be vaccinated based on shared clinical decision-making. Give 2 doses of either MenB vaccine: Bexsero, spaced 1m apart; Trumenba, spaced 6m apart.
- For children age 10yrs and older with persistent complement component deficiencies or complement inhibitor use, functional or anatomic asplenia, including sickle cell disease, or who are at risk during a community outbreak attributable to a vaccine serogroup and 2) children age 2m and older traveling to or living in countries with hyperendemic or epidemic meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj.

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>Schedule for routine vaccination and other guidelines (any vaccine can be given with another, unless otherwise noted)</th>
<th>Schedule for catch-up vaccination and related issues</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
</table>
| **Meningococcal conjugate, quadrivalent (MenACWY)** | • Give a 2-dose series of MenACWY with dose #1 at age 11–12yrs and dose #2 at age 16yrs.  
  • If unvaccinated at 11–12yrs, give dose #1 at age 13 through 15yrs. Give dose #2 at 16 through 18yrs with a minimum interval of at least 8wks between doses.  
  • If unvaccinated at 11 through 15yrs, give dose #1 at 16 through 18yrs.  
  • For first year college students living in a residence hall, regardless of age:  
    - If unvaccinated, give 1 dose.  
    - If history of 1 dose given when younger than age 16, give dose #2.  
    - If most recent dose given after 16th birthday and more than 5 years have elapsed, give 1 dose.  
  • Give Menveo to children age 2–18m with persistent complement component deficiency, complement inhibitor use, HIV infection, or anatomic/functional asplenia; give at ages 2, 4, 6, 12–15m.  
  • For unvaccinated or partially vaccinated children age 7–23m with persistent complement component deficiency: 1) if age 7–23m and using Menveo, give a 2-dose series at least 3m apart with dose #2 given after age 12m or, 2) if age 9–23m and using Menactra, give a 2-dose series at least 3m apart. Give any brand of MenACWY to unvaccinated children age 24m and older with persistent complement component deficiency or anatomic or functional asplenia; give 2 doses, 2m apart. If Menactra is given, it must be separated by 4wks from the final dose of PCV13.  
  • Give age-appropriate series of meningococcal conjugate vaccine (brand must be licensed for age of child) to 1) children age 2m and older at risk during a community outbreak attributable to a vaccine serogroup and 2) children age 2m and older traveling to or living in countries with hyperendemic or epidemic meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj. | • If previously vaccinated and risk of meningococcal disease persists, revaccinate with MenACWY in 3yrs (if previous dose given when younger than age 7yrs) or in 5yrs (if previous dose given at age 7yrs or older). Then, give additional booster doses every 5yrs if risk continues.  
  • Minimum ages: 2m Menveo; 9m Menactra; 2yrs MenQuadfi.  
  • A catch-up dose of MenACWY may be given at age 19 through 21yrs to those who did not receive a dose after their 16th birthday.  
  • If using Menactra in a high-risk child, it should be given before or at the same visit as DTaP is administered.  
  • MenACWY vaccine may be given concomitantly with MenB vaccine. | **Contraindication**  
  • History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component.  
  • For MenACWY-D and MenACWY-CRM only: severe allergic reaction to any diphtheria toxoid- or CRM197-containing vaccine.  
  • For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine.  
  | **Precaution**  
  • Moderate or severe acute illness, with or without fever.  
  • For MenACWY-CRM only: preterm birth if younger than age 9m. |
| **Meningococcal serogroup B (MenB)** | • Teens age 16 through 18yrs may be vaccinated based on shared clinical decision-making. Give 2 doses of either MenB vaccine: Bexsero, spaced 1m apart; Trumenba, spaced 6m apart.  
  • For children age 10yrs and older with persistent complement component deficiencies or complement inhibitor use, functional or anatomic asplenia, including sickle cell disease, or who are at risk during a community outbreak attributable to a vaccine serogroup and 2) children age 2m and older traveling to or living in countries with hyperendemic or epidemic meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj. | • At-risk children (see 2nd bullet in column to left) should receive a 1-dose booster 1 year after completing the primary series, followed by boosters every 2–3 years if risk continues.  
  • Minimum age: 10yrs.  
  • The brands of MenB vaccine are not interchangeable. If the brand of MenB vaccine used for the primary series is unknown or unavailable, complete a primary series with the available brand.  
  • MenB vaccine may be given concomitantly with MenACWY vaccine. | **Contraindication**  
  • History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to a vaccine component.  
  • Pregnancy.  
  • For MenB-4C only: latex sensitivity. | **Precaution**  
  • Moderate or severe acute illness, with or without fever.  
  • Pregnancy.  
  • For MenB-4C only: latex sensitivity. |